The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Trodelvy and Keytruda combination shows promise in treating advanced triple-negative breast cancer, improving ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

A new clinical trial has shown that combining Gilead Sciences, Inc. (NASDAQ:GILD)’s Trodelvy with Merck & Co., Inc. (NYSE:MRK)’s immunotherapy Keytruda significantly reduces the risk of disease ...

Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study. Data from the phase III ASCENT-04 ...

Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35 per cent when used as an initial ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...